最新

  • 维多利亚港商贸联合协会会长尹德辉探讨未来数字香港

    4月12日,数字经济峰会在香港会议展览中心如期举行。本次峰会以「智创无限 成就可持续未来」为主题,旨在探讨数字经济发展对香港未来发展的深远影响。
  • “古韵丹青卷 诗画青木川”

    春风拂面,我们迎来了充满活力和生机的五一劳动节。在这个特别的日子里,青木川景区特别策划了一场以“古韵丹青卷 诗画青木川”为主题的文化庆典活动,此次活动将带您领略青木川古镇的韵味,品味古文化的博大精深,共同感受诗画般的美丽风景。
  • 沭阳佳品生鲜配送有限公司

    沭阳佳品生鲜配送有限公司,成立于2021年7月28日,是一家集“种植、养殖、加工、销售、运输、检测”于一体的综合企业。致力于向学校、企事业单位食堂提供安全、新鲜、健康、营养的餐饮原材料采购、配送及相关配套服务的专业公司。产品包括米面油、调味品、果蔬、肉类产品、冷冻品、豆制品等多种类。
  • 2024年关于Bitop的全面评测

    投资者一直在迅速发展的加密市场和传统金融行业中,积极寻求多样化的投资机会。面对众多投资选项,投资者希望找到一个涵盖加密、商品、股票、现货和衍生品等多种投资产品的平台。
  • 晶科能源获评彭博BNEF Tier1全球一级储能厂商!

    近日,彭博新能源财经(BloombergNEF)公布了《BNEF Energy Storage Tier 1 List 2Q 2024》(彭博储能系统2024二季度第一梯队厂商榜单),晶科能源凭借在储能领域的卓越实力荣登榜单。
  • 全宇宙国度!All Universe全宇宙平台全球上线!

    在当下的金融市场中,投资已经成为人们实现财富增值的重要手段之一。然而,对于普通投资者来说,如何进行优质的资产配置依然是个难题。好在随着越来越专业和优质的财富管理机构的出现,给广大投资者们在资产配置和财富保值增值之路上提供了更多的指引和协助。
  • 中国旅游协会饮食文化专业工作委员会成立仪式暨饮食文化传承与创新研讨会在上海召开

    4月15日,中国旅游协会饮食文化专业工作委员会成立仪式在上海苏宁宝丽嘉酒店举行。中国旅游协会秘书处领导、中国旅游协会饮食文化专业工作委员会主任单位和委员单位以及业界同仁近百余人出席了本次活动。中国旅游协会副秘书长佘小殷主持会议。
  • 辉山零蔗糖花生牛奶上市 响应健康消费趋势和乡村振兴政策

    乘着健康生活的东风,辉山牛奶将小粒花生的浓郁风味融入新品零蔗糖花生牛奶中,巧妙地抓住了年轻消费者的喜好,推出营养新品零蔗糖花生牛奶,浓郁的花生香气与醇厚的奶香在口中交织,口感丝滑顺腻,些许香甜又回味无穷。辉山在滋味的调色盘上,挥洒着创意,不仅给健康饮品市场带来一股清新的潮流,还为乡村的繁荣播下了生机勃勃的种子,将智慧与情感结合起来,让人连连称赞。
  • 辉山零蔗糖花生牛奶新品上市 健康新品赋能乡村经济发展

    乘着健康生活的东风,辉山牛奶将小粒花生的浓郁风味融入新品零蔗糖花生牛奶中,巧妙地抓住了年轻消费者的喜好,推出营养新品零蔗糖花生牛奶,浓郁的花生香气与醇厚的奶香在口中交织,口感丝滑顺腻,些许香甜又回味无穷。辉山在滋味的调色盘上,挥洒着创意,不仅给健康饮品市场带来一股清新的潮流,还为乡村的繁荣播下了生机勃勃的种子,将智慧与情感结合起来,让人连连称赞。

友情链接

Celartics Biopharma's dendritic cell-based vaccine against COVID-19 infection found to efficiently produce viral antigen-specific T lymphocytes

2020-05-22    

Results from ongoing study suggest the major role of Celartics' Cov-DCVax in preventing viral infection of COVID-19 and in controlling progression of the virus-associated diseasesBeijing, May 22, 2020, Celartics Biopharma announced today the filing of a patent application covering a novel dendritic cell (DC)-based vaccine, Cov-DCVax, to fight viral infection of COVID-19. The results, led by Celartics research team, demonstrate that using the proprietary engineered DC technology by targeting nucleoprotein (NP) of COVID-19, NP-specific cytotoxic CD8+ T cells from naive T lymphocytes can be efficiently induced and massively expanded in culture. The antigen-loaded DCs and viral antigen-specific T cells have great potentials in preventing viral infection and in controlling progression of virus-associated diseases, respectively.

Dendritic cells are the most potent professional antigen-presenting cells that can engulf and process viral or tumor antigens. Once DCs are loaded with viral antigen and become activated, they acquire the ability to educate naïve T lymphocytes, promoting these T cells to differentiate into antigen-specific cytotoxic T cells that can fight virus. Primary blood DCs constitute 1% of immune cells in peripheral blood and are not able to grow in culture. Manufacturing clinical grade DC with the conventional DC method, therefore, needs quite large amount of blood and is very costly, limiting DC’s application as a preventive vaccine against viral infection. To overcome various technical hurdles associated with the conventional DC method, Celartics Biopharma has developed an innovative engineered DC technology, which enables primary blood DCs from a few milliliters of peripheral blood to grow in culture, generating large amounts of highly activated DCs suitable for multiple clinical applications. These engineered DCs exhibit vastly improved antigen-loading capability and efficient lymphoid tissue homing ability due to high expression of the chemokine receptor, CCR7. In addition, the manufacturing cost for generating engineered DCs is significantly reduced. “The engineered DCs are safe to use, as demonstrated in animal studies and pilot clinical trial in cancer immunotherapy”, said Yang Yu, CEO of Celartics Biopharma

Current vaccine strategies for COVID-19 include mRNA vaccine, DNA vaccine, adenovirus vector-based vaccine and inactivated virus vaccine, with the goal of generating neutralizing antibody that reacts to Spike, the viral surface protein of COVID-19. The neutralizing antibody blocks entry of virus to host cells through ACE2 receptor. Accumulating evidences have suggested that developing permanent immunity remains challenging, exclusively by targeting heavily glycosylated Spike protein or rapidly mutating viral surface proteins such as influenza HA. Differing from these vaccine strategies, the engineered DCs are designed to empower T cells to fight virus. DC-educated T cells recognize viral antigenic peptides complexed with HLA molecules on the surface of virus-harboring host cells and launch subsequent attack to eliminate virus. Furthermore, a given viral protein in host cells is processed into multiple antigenic peptides that are bound to distinct HLA molecules, this provides many targets for antigen-specific T cells to attack. Unlike Spike protein, the NP protein of COVID-19 is less likely to mutate and also share 91% amino acid sequence homology with the counterpart of SARS virus. “The Cov-DCVax is designed to develop long-lasting protective immunity in human to fight both COVID-19 and SARS viruses”, said Yang Yu.

In last February, Celartics Biopharma announced the development of Human Dendritic Cell and Data Repository (HDCR), in order to meet urgent demands in fighting deadly virus outbreak and cancer. HDCR prepares human blood dendritic cells from healthy individuals in GMP facility, coupled with data analysis covering immunophenotyping and HLA typing. These engineered DCs are stored in liquid nitrogen and are readily available when needed, in supporting cell-based vaccination or immunotherapy. HDCR also serves as the platform technology provider to research institutions and pharmaceutical industries. The ultimate goal of HDCR is to bring in a feasibility of dendritic cells as a new form of preventive vaccines for rapidly evolving viruses. The Cov-DCVax vaccine is intended for generating long-lasting protective immunity in high risk individuals, while the viral antigen-specific T cells provide immediate therapeutic protection in controlling the progression of COVID-19-associated disease. "The current research progress and patent application enhance the spectrum of possible collaborators and partners. We are delighted that our scientific team has made solid progress in developing such unique Cov-DCVax vaccine, which may potentially yield benefits useful to high risk population, considering current global impact and severity of COVID-19 pandemic", said Yang Yu, CEO of Celartics Biopharma.


About Celartics Biopharma, Inc. Celartics Biopharma is a biotechnology company, located at Dongsheng International Science Park, Beijing. The company focuses on developing innovative cell-based immunotherapies for human cancer and viral diseases. The Company seeks rapidly advancing these technologies through pre-clinical and Phase I and II clinical trials, centering on DC therapeutic vaccine and adoptive T cell transfer therapies for treating solid cancer and leukemia. The company also seeks potential collaborators and partners for joint development through the proprietary technology platforms.

Ph.D., Chief Technology Officer, Celartics Biopharma, Inc.

Company :Celartics Biopharma Inc., Ltd.  

Contact: Huan Zhang,

Phone:010-6295 5880

Email: lily@celartics.com

Web:http://www.celartics.com/


免责声明:本文转载自其它媒体,转载目的在于传递更多信息,并不代表本网赞同其观点和对其真实性负责,亦不负任何法律责任。 本站所有资源全部收集于互联网,分享目的仅供大家学习与参考,如有版权或知识产权侵犯等,请给我们留言。
返回顶部
©版权 2009-2020 平阳网      联系我们   SiteMap